Skip to main content
RPRX logo

Royalty Pharma plc (RPRX) Stock: Price, Forecast & Analyst Target

Royalty Pharma plc (RPRX) — MoonshotScore 73/100 (Strong band), calculated Nov 18, 2026. Price $68.67 (-0.01%), as of the Nov 18, 2026 trading session; market cap $39.5B.

Educational signal · not a buy or sell recommendation · How to read this

$68.67 −$0.01 (-0.01%) Market Cap $39.5B

Royalty Pharma plc · RPRX · NASDAQ · Healthcare · Medical Pharmaceuticals

Research dated 2026-09-12: Royalty Pharma buys biopharmaceutical royalty rights and funds drug innovation; it owns cash flow claims on therapies rather than operating as a conventional medicine manufacturer. Its appeal and risk meet at the same point: whether portfolio receipts can support new royalty purchases, dividends, and a debt-heavy capital structure without sustained pressure on liquidity.

Price as of Nov 18, 2026

Key Statistics

73 of 100

MoonshotScore v2 · Royalty Pharma (RPRX)

Strong
Business Quality Elite (89)
Financial Safety Strained (27)
Valuation Full (52)
Growth Durability Flat (43)
Momentum Surging (94)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Elite quality, but a strained balance sheet and a full valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Strained; Valuation: Full; Growth Durability: Flat; Momentum: Surging.

  • EPS beat 8 of the last 8 reports
  • Altman Z 2.49 · Piotroski F 6
  • ROE 12.1% · ROA 5.4% · current ratio 1.29

Holding back: balance-sheet strain

Helping: business quality, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for RPRX (57 recorded, newest six shown)
RecordedScoreBand
75Strong
74Strong
73Strong
73Strong
73Strong
73Strong

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$68.67
Change on the day-0.01%
52-week range$37.31–$70.37
Market capitalisation$39.5B—
Price / earnings (trailing)41.12
Shares traded on the day3.19M
Beta (volatility vs the S&P 500)0.41

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 18, 2026: low $37, high $69, latest $69. $69 $37 high $69 Oct 17, 2025 Nov 18, 2026 · $69 $37Oct 17, 2025$38Oct 31, 2025$39Nov 14, 2025$40Nov 28, 2025$38Dec 12, 2025$39Dec 26, 2025$40Jan 9, 2026$40Jan 23, 2026$45Feb 6, 2026$45Feb 20, 2026$45Mar 6, 2026$45Mar 20, 2026$49Apr 2, 2026$50Apr 17, 2026$49May 1, 2026$53May 15, 2026$56May 29, 2026$55Jun 12, 2026$56Jun 26, 2026$56Jul 10, 2026$59Jul 24, 2026$57Aug 7, 2026$61Aug 21, 2026$64Sep 4, 2026$58Sep 18, 2026$57Oct 2, 2026$61Oct 16, 2026$67Oct 30, 2026$69Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for Royalty Pharma (RPRX): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Strong
Financial Safety Weak
Valuation Neutral
Growth Durability Neutral
Momentum Strong

Legends Council

4 lenses, 4 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Griffin-style lens (simulated) Ken Griffin Unfavorable read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Strong
Revenue Growth Neutral
Debt/Equity Weak
ROE Moderate
Gross Margin Strong

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

Two of these lenses read this company less favourably than the MoonshotScore does: Griffin-style lens and Klarman-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Royalty Pharma (RPRX), and what does it report?

Short answer · as of

Royalty Pharma purchases economic interests in marketed therapies and development-stage candidates across several therapeutic areas.

Its healthcare classification places it alongside pharmaceutical companies, but its revenue comes from royalty assets rather than selling medicines it manufactures.

Financial Royalty Assets generate nearly all reported segment revenue, with Royalty Income, Other contributing a much smaller portion. The income statement records accounting revenue and profit from this portfolio, while operating cash flow captures cash generation; the latest series shows that those measures do not always move together.

2 · Latest results

What do the latest results show for Royalty Pharma (RPRX)?

Quarterly revenue advanced from the prior period, yet gross profit, operating profit, net result, and diluted earnings all fell sharply. Research and development expense increased, while selling, general, and administrative expense remained elevated, so the latest top-line gain did not translate into comparable earnings.

Recent earnings releases have shifted from revenue shortfalls to revenue and earnings beats. Management has also raised guidance and continues to describe the longer-run growth profile as strong and low volatility, but that claim sits beside pronounced quarterly profit swings and must be judged separately from estimate comparisons.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026Not availableNot availableNot availableNot available
Jun 30, 2026Not availableNot availableNot availableNot available
Mar 31, 2026Not availableNot availableNot availableNot available
Dec 31, 2025Not availableNot availableNot availableNot available
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2025$609M$284M$0.66 (diluted)
Q4 FY2025$622M$214M$0.50 (diluted)
Q1 FY2026$631M$295M$0.67 (diluted)
Q2 FY2026$674M$18M$0.04 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Royalty Pharma (RPRX)?

Short answer · as of

Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.

Operating cash flow has remained substantial throughout the reported window, with no capital expenditure recorded, reflecting the capital-light nature of owning royalty interests. Trailing margins and free-cash-flow yield also point to strong portfolio economics, while recurring dividends return part of that cash to shareholders.

Balance-sheet flexibility is more constrained than cash generation alone suggests. Cash and short-term investments declined materially across the reported window before recovering in the latest period, and total debt remains far above cash and investments. Weaker receipts from underlying therapies or disappointing progress among development-stage candidates would therefore meet continuing financial obligations from a less comfortable liquidity position.

4 · What to check next?

What should you watch next at Royalty Pharma (RPRX)?

Short answer · as of

Current published price targets run low $66.00 · high $67.00 · consensus $66.50 · median $66.50 against a quoted price of $68.67 (as of Nov 18, 2026).

At the scheduled earnings release, compare reported revenue and earnings with expectations, but give greater weight to whether operating cash flow remains durable and the latest cash recovery continues. Recent estimate beats raised expectations; they did not remove the gap between liquid resources and debt.

Research and development expense, administrative expense, operating profit, and net result deserve close attention after their latest swings. Management’s raised guidance and low-volatility growth claim would gain support from sustained revenue, cash conversion, and earnings progress rather than an isolated favorable comparison with forecasts.

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Royalty Pharma compare with its peers?

Short answer

Royalty Pharma's score ranks 12th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Conventional biopharmaceutical companies depend on their own research, approvals, manufacturing, and commercialization. Royalty Pharma instead acquires or funds economic rights tied to therapies developed and sold by others, spreading its portfolio across marketed products and development candidates.

The small employee base, absence of reported capital expenditure, and high margins fit a scalable financial-asset model more closely than a laboratory or manufacturing network. Scientific underwriting, partnering, deal selection, and capital allocation are therefore central operating capabilities, while leverage makes the price and funding of royalty acquisitions especially consequential.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Exelixis, Inc. (EXEL) Same industry, near in market value$68.29 Nov 18, 2026$16.7B98 5-pillar Nov 18, 2026
United Therapeutics Corporation (UTHR) Named competitor$577.34 Nov 18, 2026$24.6B97 5-pillar Nov 18, 2026
argenx SE (ARGX) Same industry, near in market value$941.25 Nov 18, 2026$59.2B96 5-pillar Nov 18, 2026
Ascendis Pharma A/S (ASND) Same industry, near in market value$270.33 Nov 18, 2026$17.7B96 5-pillar Nov 18, 2026
Neurocrine Biosciences, Inc. (NBIX) Same industry, near in market value$162.86 Nov 18, 2026$16.5B95 5-pillar Nov 18, 2026
Regeneron Pharmaceuticals, Inc. (REGN) Same industry, near in market value$945.53 Nov 18, 2026$97.8B95 5-pillar Nov 18, 2026
Halozyme Therapeutics, Inc. (HALO) Same industry, near in market value$95.80 Nov 18, 2026$10.9B95 5-pillar Nov 18, 2026
Bio-Techne Corporation (TECH) Same industry, near in market value$72.75 Nov 18, 2026$11.4B92 5-pillar Nov 18, 2026
Incyte Corporation (INCY) Named competitor$117.80 Nov 18, 2026$24.0B91 5-pillar Nov 18, 2026
Vertex Pharmaceuticals Incorporated (VRTX) Same industry, near in market value$536.45 Nov 18, 2026$136B90 5-pillar Nov 18, 2026
TG Therapeutics, Inc. (TGTX) Same industry, near in market value$66.12 Nov 18, 2026$9.99B90 5-pillar Nov 18, 2026
Royalty Pharma (RPRX) — this page$68.67$39.5B73
Genmab A/S (GMAB) Named competitor$50.97 Nov 18, 2026$31.4B72 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$66.00 – $67.00
Consensus target
$66.50
Median target
$66.50

Consensus record · Captured .

Measured against a quoted price of $68.67 (as of Nov 18, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 6, 2026

Transactions
44
Identified insiders
12
Purchases
0
Sales
16
Other transactions
28

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held RPRX in their latest 13F filing, and what they did against the filing before it.

InvestorManager13F quarterPortfolio weightValueLast quarter
Bridgewater AssociatesFounded by Ray DalioQ3 20260.12%$27.69MAdded +116.0% shares

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Royalty Pharma (RPRX)?

Read these with our analysis →

Common Questions About RPRX (Healthcare)

The last 2 questions are answered from this page's own dated data, not from the research.

Why do Financial Royalty Assets dominate Royalty Pharma’s revenue?

Acquired royalty interests, rather than conventional product sales, produce nearly all segment revenue. Therapy-level cash economics and acquisition discipline are therefore more informative than manufacturing volume.

How can Royalty Pharma grow without launching its own medicines?

Royalty receipts can expand as partnered therapies generate more sales or as Royalty Pharma acquires and funds additional rights. Development-stage candidates add potential future royalty streams, though their contribution depends on clinical and commercial progress.

What could break Royalty Pharma’s low-volatility growth claim?

Weak royalty receipts, setbacks among development-stage candidates, or continued swings in expenses and reported profit would challenge that claim. Persistent liquidity pressure alongside substantial debt would make such operating disappointments more consequential.

How should investors reconcile Royalty Pharma’s cash generation with its debt?

Operating cash flow is strong and reported capital expenditure is absent, but debt greatly exceeds cash and investments. That cash generation can support dividends and royalty purchases, yet it does not eliminate the importance of disciplined capital allocation and financial obligations.

What is the RPRX stock price today?

The last price recorded for Royalty Pharma plc (RPRX), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the RPRX price target?

The analyst consensus price target for Royalty Pharma plc (RPRX), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 25 figures on this page — 1 from SEC filings and earnings calls, 20 from Financial Modeling Prep (FMP), 3 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-12), by section of the research

  • Summary at the top of the page: Business description; Revenue by segment; Operating cash flow by quarter (USD millions); Cash, investments and debt; Recent dividends paid
  • 1. What is Royalty Pharma (RPRX), and what does it report?: Sector / industry (provider taxonomy); Business description; Revenue by segment; Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Operating cash flow by quarter (USD millions)
  • 2. What do the latest results show for Royalty Pharma (RPRX)?: Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Reported versus estimated, last 8 quarters; Management outlook — dated call excerpts; Most recent periodic reports
  • 3. What are the financial strengths and risks for Royalty Pharma (RPRX)?: Operating cash flow by quarter (USD millions); Trailing twelve-month ratio set; Recent dividends paid; Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash decline over the reported window; Cash against market value; Business description
  • 4. What should you watch next at Royalty Pharma (RPRX)?: Next earnings report; Reported versus estimated, last 8 quarters; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash and short-term investments over time (USD millions); Cash, investments and debt; Management outlook — dated call excerpts
  • 5. How does Royalty Pharma compare with its peers?: Business description; Employees; Named officers; Operating cash flow by quarter (USD millions); Trailing twelve-month ratio set; Cash, investments and debt; Revenue by segment
  • FAQ: Why do Financial Royalty Assets dominate Royalty Pharma’s revenue?: Revenue by segment; Business description
  • FAQ: How can Royalty Pharma grow without launching its own medicines?: Business description; Revenue by segment
  • FAQ: What could break Royalty Pharma’s low-volatility growth claim?: Management outlook — dated call excerpts; Business description; Quarterly income statement (USD thousands); Cash, investments and debt; Cash and short-term investments over time (USD millions); Cash decline over the reported window
  • FAQ: How should investors reconcile Royalty Pharma’s cash generation with its debt?: Operating cash flow by quarter (USD millions); Cash, investments and debt; Cash and investment components; Cash against market value; Recent dividends paid; Business description
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.

ETFs that hold RPRX

Funds in our ETF coverage that list RPRX among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.

ETFWeightHoldings as of
Eventide High Dividend ETF (ELCV)3.10%
Global X - Adaptive U.S. Factor ETF (AUSF)2.21%